Clear all

Refine your search

Tags
Territory
Jurisdiction

738 results found

Smart & Biggar logo
Smart & Biggar is Canada's largest firm practising exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montreal…
Commentary
Ask Lexy

Smart & Biggar | Canada | 20 Sep 2021

Fact or fiction? Debunking patent myths for business and technology leaders

There are many misconceptions or "myths" about patents that have found their way into popular discourse. In this article, five common myths about patents are addressed to help business leaders and technology managers better separate fact from fiction and make informed decisions to protect investments made in innovation.
Commentary
Ask Lexy

Smart & Biggar | Canada | 15 Sep 2021

Federal Court of Appeal upholds decision finding Seedlings' LifeCard patent invalid and not infringed by Pfizer's EpiPen

The Federal Court of Appeal recently dismissed Seedlings' appeal from the Federal Court decision of Justice Grammond, which concluded that certain claims of Seedlings' LifeCard patent were invalid and not infringed by Pfizer's next-generation EpiPen. The patent in question relates to an auto-injection device, primarily used for the administration of epinephrine in treating symptoms of......
Commentary
Ask Lexy

Smart & Biggar | Canada | 8 Sep 2021

Federal Court of Appeal remits pricing decision on Alexion's Soliris to Patented Medicine Prices Review Board

In 2017 the Patented Medicine Prices Review Board (the board) decided that Alexion's Soliris (eculizumab) was sold at an excessive price. However, the Federal Court of Appeal recently set aside the Federal Court's decision to dismiss Alexion's application for judicial review and remitted the matter to the board for redetermination, directing it "to examine the evidence, interpret the......
Commentary
Ask Lexy

Smart & Biggar | 1 Sep 2021

Health Canada TPD, BRDD and NNHPD annual performance reports released

The Therapeutic Products Directorate, the Biologic and Radiopharmaceutical Drugs Directorate and the Natural and Non-Prescription Health Products Directorate have released their drug submission performance annual reports for the fiscal year 2020-2021. The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical drug submission review activity, including average......
Commentary
Ask Lexy

Smart & Biggar | 25 Aug 2021

Federal Court of Appeal maintains award against Apotex for cefaclor patent infringement

The Federal Court of Appeal recently dismissed Apotex's appeal of the Federal Court's reconsideration decision on the quantum of damages owed by Apotex for its infringement of eight Eli Lilly process patents relating to the antibiotic cefaclor. The initial Federal Court decision, which had awarded Lilly roughly $31 million in damages and $75 million in prejudgment interest, was overturned on......
Commentary
Ask Lexy

Smart & Biggar | 18 Aug 2021

Federal Court of Appeal confirms Janssen's Spravato not eligible for data protection

In 2013 the Federal Court dismissed Janssen's application for judicial review of a decision by the minister of health that denied Janssen data protection for Spravato, a drug indicated for the treatment of major depressive disorder. Recently, the Federal Court of Appeal dismissed Janssen's appeal of the Federal Court's decision, holding that the Federal Court had not erred in finding that the......
Commentary
Ask Lexy

Smart & Biggar | 16 Aug 2021

Copyright tariffs not mandatory on works managed by collective societies

In a rare copyright decision, the Supreme Court unanimously held that copyright collectives cannot charge fees to those that decline their contracts. The case is important for both owners and users of copyrighted works in Canada. It establishes that a collective's licence and its associated tariffs are not mandatory, while reminding those that opt out and copy without permission that they may......
Commentary
Ask Lexy

Smart & Biggar | Canada | 11 Aug 2021

New consultation on PMPRB guidelines

The Patented Medicines Prices Review Board recently announced a consultation on proposed changes to the new guidelines (which, like the amendments to the Patented Medicines Regulations, are now due to come into effect on 1 January 2022). The changes include an amendment to the definition of "gap medicines" and revised international price tests.
Commentary
Ask Lexy

Smart & Biggar | Canada | 21 Jul 2021

Canada's Patented Medicines Regulations delayed and PMPRB's jurisdiction extended

The coming into force of the amended Patented Medicines Regulations has been delayed for a third time. The amendments, once in force, will add new price regulatory factors, revise the list of reference countries and modify reporting requirements for particular categories of drugs. The Patented Medicine Prices Review Board Guidelines have also been delayed until 2022.
Commentary
Ask Lexy

Smart & Biggar | Canada | 12 Jul 2021

How to record brand rights and stop counterfeit goods at the border

The Canada-United States-Mexico Agreement (CUSMA) has celebrated its first anniversary, prompting reflections on the changes that it has brought about for brand owners. With the passage of the CUSMA, the Canada Border Services Agency may now detain in-transit commercial shipments of suspected counterfeit goods travelling through Canada en route to their final destinations.
Previous page 1 2 3 ...